These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
14. [A new class of potent antihypertensive agents. Especially systolic pressure is significantly reduced]. MMW Fortschr Med; 1999 Nov; 141(47):8. PubMed ID: 10912157 [No Abstract] [Full Text] [Related]
15. [Vasopeptidase inhibition. A new mechanism of action for the treatment of hypertension and cardiac insufficiency]. Kolloch R; Offers E Internist (Berl); 2001 Feb; 42(2):290-6. PubMed ID: 11244883 [No Abstract] [Full Text] [Related]
16. Vasopeptidase inhibitors and their potential role in diabetes. Chowdhury TA; Khan T Diabetes Obes Metab; 2002 Mar; 4(2):89-95. PubMed ID: 11940105 [No Abstract] [Full Text] [Related]
18. [Omapatrilat--new drug for patients with hypertension and heart failure]. Dzielska-Olczak M Pol Merkur Lekarski; 2005 Oct; 19(112):556-8. PubMed ID: 16379325 [TBL] [Abstract][Full Text] [Related]
19. Effects of the vasopeptidase inhibitor omapatrilat on peri- and postmyocardial infarction in Zucker lean rats. Lapointe N; Parker TG; Tsoporis JN; Nguyen QT; Marcotte F; Adam A; Lou I; Rouleau JL Can J Cardiol; 2005 Mar; 21(3):291-7. PubMed ID: 15776120 [TBL] [Abstract][Full Text] [Related]